KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Five-year overall survival in JCOG1205/1206: irinotecan or etoposide plus cisplatin for resected high-grade neuroendocrine carcinoma of the lung.

Hirotsugu Kenmotsu, Seiji Niho, Masahiro Tsuboi, Masashi Wakabayashi, Genichiro Ishii, Hajime Asahina, Kana Watanabe, Moriyuki Kiyoshima, Takekazu Iwata, Yukiko Nakamura, Yoshiro Nakahara, Toyofumi Fengshi Chen-Yoshikawa, Kazumi Nishino, Wataru Nishio, Toshihide Yokoyama, Noriko Mitome, Hisao Asamura, Yuichiro Ohe, Shun-Ichi Watanabe

Lung Cancer 216 109386

PMID42000139
PMCID-
DOI10.1016/j.lungcan.2026.109386
发表日期2026-04-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

INTRODUCTION: We aimed to evaluate the long-term follow-up overall survival (OS) of irinotecan plus cisplatin (IP) versus etoposide plus cisplatin (EP) as postoperative adjuvant chemotherapy in patients with pathological Stage I-IIIA high-grade neuroendocrine carcinoma (HGNEC) of the lung. METHODS: The JCOG1205/1206 randomized, open-label, phase III study compared the efficacy of IP and EP as adjuvant chemotherapy. Patients with pathological Stage I-IIIA and completely resected HGNEC of the lung were randomized to receive either the IP or EP arm. The primary endpoint was relapse-free survival (RFS), and the secondary endpoint included overall survival (OS). The analyses were performed using data from 5 years after the last patient enrollment. In addition, a central pathological review was planned for this study. RESULTS: Between April 2013 and October 2018, 221 patients were enrolled (EP arm, 111 patients; IP arm, 110 patients). Updated respective 3- and 5-year RFS rates were 68.5% and 65.7% in the EP arm versus 71.8% and 65.2% in the IP arm, with a hazard ratio (HR) of 1.026 (95% confidence interval [CI], 0.670-1.569). OS at 3 and 5 years was 85.6% and 73.5%, respectively, in the EP arm versus 83.6% and 72.4%, respectively, in the IP arm (HR, 1.175; 95% CI, 0.742-1.861). The concordance proportion of pathological diagnoses between each institution and central pathological reviews was 75.6% (95% CI, 69.4%-81.1%). CONCLUSIONS: Our results showed no significant difference in both updated RFS and OS between the two arms for patients with completely resected HGNEC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。